It has been reported that administration of whole glucan particle (WGP) β-glucan along with PD-1/PD-L1-checkpoint-blocking antibodies leads to increased recruitment of immune-associated cells, improves the regulation of the balance between T cell activation and immune tolerance, and delays tumor progression [53]. The gene discussed is PDCD1; the disease is neoplasm.